Literature DB >> 21178332

Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.

Leandro Kasuki Jomori de Pinho1, Leonardo Vieira Neto, Luiz Eduardo Armondi Wildemberg, Emerson Leandro Gasparetto, Jorge Marcondes, Bruno de Almeida Nunes, Christina M Takiya, Mônica R Gadelha.   

Abstract

BACKGROUND: Some pituitary adenomas exhibit fast growth and invade surrounding structures. To date, there is no robust marker to predict invasiveness. AIM: To evaluate Ki-67, p53 and aryl hydrocarbon receptor-interacting protein (AIP) expression and compare these between invasive and noninvasive somatotropinomas and nonfunctioning pituitary adenomas (NFPAs).
METHODS: Protein expression was determined by immunohistochemistry. Tumors were classified according to percentage of immunolabeled nuclei for Ki-67 and p53. AIP immunopositivity was graded according to a score encompassing pattern and intensity. Invasiveness was defined according to radiological and surgical criteria.
RESULTS: Thirty-eight sporadic somatotropinomas were studied. Median Ki-67 labeling index in invasive and noninvasive tumors was 1.6 (range 0-20.6) and 0.26 (0-2.2), respectively (p = 0.01). With a 2.3% cut-off point obtained by ROC curve analysis, invasive adenomas were distinguished with 100% specificity, 39% sensitivity, and 63% accuracy. Low AIP expression was also correlated with tumor invasiveness (p = 0.001), with sensitivity, specificity and accuracy of 78, 80, and 79%, respectively. Expression of p53 was not different among tumors. Twenty-nine NFPAs were studied, with no significant difference between Ki-67, p53 and AIP expression in invasive and noninvasive tumors. High AIP expression was more frequent in NFPAs, with Ki-67 >3% (p = 0.051), especially when only gonadotrope cell adenomas (n = 25) were considered (p = 0.012).
CONCLUSIONS: These data suggest, for the first time, that AIP is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. In addition, low AIP expression is observed in invasive somatotropinomas, in contrast with high AIP expression in NFPAs (mainly gonadotrope cell tumors) with high proliferative indices.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178332     DOI: 10.1159/000322787

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  15 in total

1.  The role of AIP mutations in pituitary adenomas: 10 years on.

Authors:  Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

2.  Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.

Authors:  Raúl M Luque; Alejandro Ibáñez-Costa; Leonardo Vieira Neto; Giselle F Taboada; Daniel Hormaechea-Agulla; Leandro Kasuki; Eva Venegas-Moreno; Alberto Moreno-Carazo; María Ángeles Gálvez; Alfonso Soto-Moreno; Rhonda D Kineman; Michael D Culler; Manuel D Gahete; Mônica R Gadelha; Justo P Castaño
Journal:  Cancer Lett       Date:  2015-01-28       Impact factor: 8.679

3.  Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.

Authors:  Feng Cai; Shasha Chen; Xuebin Yu; Jing Zhang; Weiwei Liang; Yan Zhang; Yike Chen; Sheng Chen; Yuan Hong; Wei Yan; Wei Wang; Jianmin Zhang; Qun Wu
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

Review 4.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

Review 5.  The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.

Authors:  Catrin Lloyd; Ashley Grossman
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

Review 6.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

7.  Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.

Authors:  Hande Mefkure Ozkaya; Nil Comunoglu; Muge Sayitoglu; Fatma Ela Keskin; Sinem Firtina; Khusan Khodzhaev; Tugce Apaydin; Nurperi Gazioglu; Necmettin Tanriover; Buge Oz; Pinar Kadioglu
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

8.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

9.  Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.

Authors:  Judit Dénes; Leandro Kasuki; Giampaolo Trivellin; Leandro M Colli; Christina M Takiya; Craig E Stiles; Sayka Barry; Margaret de Castro; Mônica R Gadelha; Márta Korbonits
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.

Authors:  Leonardo Vieria Neto; Luiz Eduardo Wildemberg; Leandro Machado Colli; Leandro Kasuki; Nelma Veronica Marques; Aline Barbosa Moraes; Emerson L Gasparetto; Christina Maeda Takiya; Margaret Castro; Mônica Roberto Gadelha
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.